Neurology · Pain ManagementRegulatory Approvalcommercialmid-term

FDA Accepts Pregabalin ANDA211687 Submission from Alvogen

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/25/2026, 12:30:42 AM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Alvogen's ANDA for Pregabalin signifies an impending increase in market competition, which could disrupt pricing and market share dynamics. Pharma strategy teams must evaluate the implications for their own pregabalin products and prepare for potential shifts in the competitive landscape. Regulatory context from FDA (FDA AP — PREGABALIN (SUPPL)) supports the near-term read. Assessment grounded in 7 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Alvogen's entry on market share and pricing for pregabalin products. The strongest clinical anchor is Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia (ClinicalTrials.gov), sub-indication match (pain). In pain, 3 regulatory and 1 competitive items passed relevance filtering for Alvogen.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This acceptance may increase competition in the pregabalin market, impacting existing players and pricing strategies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PREGABALIN (SUPPL) (FDA). Entity match (alvogen); Regulatory pathway relevance (nda). While the acceptance of the ANDA is a positive step for Alvogen, the timeline for final approval and market launch will need to be closely monitored to assess full regulatory implications.

Key Risks

Elevated medium regulatory exposure for Alvogen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Alvogen's entry into the pregabalin market could lead to price reductions and increased competition, affecting revenue and market share for existing players.
Portfolio teams should assess the impact of Alvogen's entry on market share and pricing for pregabalin products.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for approval and potential launch dates for Alvogen's pregabalin product.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (alvogen); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Register to make submissions to the MHRA
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Popliteus Muscle Release Versus Patellofemoral Mobilization in Patellofemoral Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Ethnopharmacological validation of the antinociceptive potential of Calotropis gigantea L. flowers: Phytochemical characterization, safety evaluation, and mechanistic insights from in vivo models.
PubMedmedium relevance
Sub-indication match (pain)
FDA document
View source
Rotation-traction manipulation versus cervical traction for axial neck pain caused by cervical degenerative disc disease: a multicenter randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Targeting post-translational modifications by traditional Chinese medicine in cerebral ischemia-reperfusion injury: Recent advances.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Noninvasive imaging for the evaluation of JAK inhibitors efficacy in the management of facial vitiligo.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Alvogen
Pregabalin

Commercial impact

medium

Alvogen's entry into the pregabalin market could lead to price reductions and increased competition, affecting revenue and market share for existing players.

Regulatory impact

medium

While the acceptance of the ANDA is a positive step for Alvogen, the timeline for final approval and market launch will need to be closely monitored to assess full regulatory implications.

What to watch

Monitor the timeline for approval and potential launch dates for Alvogen's pregabalin product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.